|
| Exchange Received Time 27/08/2018 15:27:40 Exchange Disseminated Time 27/08/2018 15:27:48 Time Taken 00:00:08 | Panacea Biotec Ltd. ('Panacea Biotec') is pleased to announce that the Company has entered into a tripartite agreement with Natco Pharma Ltd. ('Natco') and Breckenridge Pharmaceutical Inc. ('Breckenridge') for the manufacture and supply of Azacitidine Injection for the U.S. market under Breckenridge's already-approved ANDA. Azacitidine is a generic equivalent of Vidaza®, which is marketed by Celgene Corporation, U.S.
As per the terms of the agreement, Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec's facility located at Baddi, Himachal Pradesh, India. Panacea Biotec will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the U.S.
A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please.
Kindly acknowledge the receipt.
|
|
|